Consensus Chemed Corporation

Stocks

CHE

US16359R1032

Healthcare Facilities & Services

Market Closed - NYSE 01:30:02 31/10/2026 am IST			5-day change	1st Jan Change
534.72 ^USD	-1.33%		+2.80%	+24.98%

29/10	UBS Adjusts Price Target on Chemed to $675 From $650, Keeps Buy Rating	MT
29/10	Oppenheimer Adjusts Price Target on Chemed to $625 From $590, Maintains Outperform Rating	MT

Evolution of the Average Target: Chemed Corporation

Evolution of the Target Price: Chemed Corporation

Changes in Analyst Recommendations: Chemed Corporation

13ef0126.B44gVJPnhSr78mA22ZIl4DS2_m0bgYBQcqlBj_xX83c.SOxpB-bf3VuriCZRvtdRtGTCmTpKzscpNccSw6MfgTRAuBg_-4XsRp-fDw~014933baacbfaf67b7a6822448b550a8

Analysts' recommendations: Chemed Corporation

29/10	UBS Adjusts Price Target on Chemed to $675 From $650, Keeps Buy Rating	MT
29/10	Oppenheimer Adjusts Price Target on Chemed to $625 From $590, Maintains Outperform Rating	MT
29/10	RBC Raises Price Target on Chemed to $585 From $548, Keeps Sector Perform Rating	MT
28/10	Chemed Q3 Beat, Guidance Raise Reflect Vitas Strength, BofA Says	MT
28/10	BofA Adjusts Price Target on Chemed to $555 From $550, Keeps Neutral Rating	MT
28/10	BofA Adjusts Price Target on Chemed to $555 From $550, Keeps Buy Rating	MT
28/10	Jefferies Upgrades Chemed to Buy From Hold, Price Target is $620	MT
28/10	Analyst recommendations: Boeing, Qiagen, Spotify, Applovin, Fedex…
25/09	UBS Initiates Chemed at Buy With $650 Price Target	MT
31/07	Oppenheimer Adjusts Price Target on Chemed to $590 From $500, Maintains Outperform Rating	MT
30/07	RBC Raises Price Target on Chemed to $548 From $436, Keeps Sector Perform Rating	MT
30/07	The Fed Gets a Better Inflation Number
30/07	Analysts recommendations: Humana, Lam Research, Procter & Gamble, Carvana, Fair Isaac…
27/04	Chemed' VITAS Continues to Build Momentum, RBC Says	MT
27/04	RBC Lifts Price Target on Chemed to $436 From $422, Keeps Sector Perform Rating	MT
31/03	Chemed Can Unlock Value From Roto-Rooter Unit, Oppenheimer Says	MT
28/02	Chemed's Roto-Rooter Unit Faces Cost Pressures as Hospice Segment Looks Bullish, RBC Says	MT
27/02	Oppenheimer Adjusts Price Target on Chemed to $500 From $580, Maintains Outperform Rating	MT
27/02	RBC Downgrades Chemed to Sector Perform From Outperform, Cuts Price Target to $422 From $572	MT
22/01	Jefferies Downgrades Chemed to Hold From Buy, Adjusts Price Target to $475 From $550	MT
22/01	Analyst recommendations: Datadog, Albemarle, Halliburton, Netflix…
10/11	RBC Lowers Price Target on Chemed to $572 From $589, Keeps Outperform Rating	MT
04/11	Analysts recommendations: Apple, Comcast, Crocs, Eli Lilly, Palantir…
02/25/02	Analysts recommendations: Acuity, Block, Elf Beauty, Fortinet, Nvidia…
02/25/02	Jefferies Upgrades Chemed to Buy From Hold, Adjusts Price Target to $550 From $490	MT

More recommendations

Other Healthcare Facilities & Services

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CHEMED CORPORATION					+13.85%
	CVS HEALTH CORPORATION					+27.84%
	HCA HEALTHCARE, INC.					-1.71%
	NATERA, INC.					-4.5%
	LABCORP HOLDINGS INC.					+1.43%
	FRESENIUS SE & CO. KGAA					+20.02%
	QUEST DIAGNOSTICS INCORPORATED					+1.72%
	TENET HEALTHCARE CORPORATION					+5.85%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+19.93%
	IHH HEALTHCARE					+31.59%
	Average					+11.60%
	Weighted average by Cap.					+10.59%